CHEMOTHERAPY FOR MULTIPLE-MYELOMA
CHEMOTHERAPY FOR MULTIPLE-MYELOMA
复制标题
DOI：
10.1002/1097-0142(19840201)53:3
复制
发表时间：
1984-01-01
期刊：
影响因子：
6.2
通讯作者：
DREICER, R
中科院分区：
文献类型：
--
作者：
ALEXANIAN, R;DREICER, R
对256例多发性骨髓瘤患者进行了8种不同药物联合治疗的疗效评价。[包括使用环磷酰胺C、阿霉素(A)、泼尼松(P)、马法兰(M)、顺铂(V)和双氯乙基亚硝脲(B)的组合是：CAP；VCAP；VMCP对无反应者早期VCAP；VBAP；VMCP/VCAP(交替)；VMCP×3/VBAP。3(顺序)；MP；和VCP。]将长春新碱和阿霉素(阿霉素)同时加入烷化剂-泼尼松的方案中，缓解率和缓解时间均优于联合方案。在试图实现更显著的肿瘤减少和推迟耐药亚克隆出现的情况下，评估的两种交替药物组合在应答率或生存时间方面没有改善。在缓解维持期间加入左旋咪唑并不能延长生存时间。结果支持在选定的骨髓瘤细胞质量显著减少的患者中进行非维持缓解随访的实用性。
The effects of 8 different drug combinations were evaluated in 256 patients with multiple myeloma. [The combinations, which involved the use of cyclophosphamide C), Adriamycin (A), prednisone (P), melphalan (M), dincristine (V) and bischloroethyl-nitrosourea (B), were: CAP; VCAP; VMCP with early VCAP to nonresponders; VBAP; VMCP/VCAP (alternating); VMCP .times.3/VBAP .times. 3(sequential); MP; and VCP.] The response rate and time to remission were superior from regimens that added both vincristine and Adriamycin (doxorubicin) to an alkylating agent-prednisone combination. There was no improvement in response rate or survival time from 2 alternating drug combinations evaluated in an attempt to achieve more marked tumor reductions and to delay the emergence of resistant subclones. The addition of levamisole during remission maintenance did not improve survival time. Results supported the utility of unmaintained remission follow-up in selected patients with marked reductions in myeloma cell mass.